new glp 1 agonist for weight loss GLP-1 Medications: Everything You Need to Know Study finds GLP-1 receptor agonists

Trends in discontinuation by indication Side effects were consistently the top reason for stopping treatment for patients receiving ADM and AOM GLP-1s

A meta-analysis across randomized controlled trials found significant reductions in body weight averaging 12.4%, BMI by 4.0 kg/m2, and waist circumference by 8.0 cm

Novo Nordisk also stated that it retains 60% of the cost and the other 40% goes to middlemen in the complex US health system

Abstract The GLP-1 RAs have become popular because of their efficacy and durability in relation to glycemic control and their low risk of hypoglycemia in combination with weight loss in most patients

mSphere 5 (1), e00585-19

Patients can reduce their risk by avoiding excessive alcohol consumption and speaking with their healthcare provider if they experience persistent abdominal pain